uniQure CEO Matthew Kapusta Sells Shares

Matthew Kapusta, the CEO of uniQure N.V., sold 4,656 shares of the company on June 18, 2026. This transaction was not part of a pre-planned trading program. The shares were sold at an undisclosed price, although the stock traded near $46.37 on the NasdaqGS on Monday.

Insider Buying and Selling at uniQure N.V.

On June 18, 2026, Matthew Kapusta, CEO and Managing Director of uniQure N.V., sold 4,656 shares. This sale was not planned under a Rule 10b5-1 trading plan. On the same day, Kapusta also bought 4,656 shares at an average price of $31.71. Additionally, on June 17, 2026, Kapusta sold 62,581 shares, and Madhavan Balachandran sold 11,685 shares at an average price of $45.06 under a planned sale.

Other Institutional Activity in uniQure N.V.

Several institutional investors adjusted their holdings in uniQure N.V. AVORO Capital Advisors LLC reduced its stake by 190,405 shares, leaving it with 5,959,595 shares valued at approximately $97.4 million. Aberdeen Group PLC increased its position by 1,627,746 shares, now holding 5,306,386 shares worth about $86.8 million. JPMorgan Chase & Co trimmed its holdings by 97,160 shares, ending with 2,837,466 shares valued at $41.8 million. Two Sigma Investments, LP significantly boosted its stake by 1,224,587 shares, reaching 2,675,871 shares valued at $43.8 million. RTW Investments, LP cut back by 1,125,106 shares, resulting in 2,586,356 shares worth approximately $42.3 million.

uniQure N.V. Stock Down 6.1%

Shares of NasdaqGS:QURE traded near $46.37 on Monday. uniQure N.V. has a market capitalization of about $2.92 billion. The company is not currently profitable, with a forward P/E ratio of -15.58. The stock's beta is 1.001, indicating it moves roughly in line with the market. Over the past 52 weeks, the stock has ranged from a low of $8.73 to a high of $71.50. Its 50-day moving average stands at $24.13, while the 200-day moving average is $27.53. The company maintains a strong liquidity position with a current ratio of 10.40 and a quick ratio of 9.97, though it has a high debt-to-equity ratio of 365.37.

Analysts Set New Price Targets

On June 18, 2026, Barclays upgraded uniQure N.V. to a 'buy' rating with a price target of $65. Goldman Sachs maintained a 'hold' rating, setting a target of $46. Leerink Partners and RBC Capital both maintained 'buy' ratings, with price targets of $70 and $65, respectively. The consensus among analysts is a 'strong buy', with a mean target price of $58.75 from 11 opinions.

About uniQure N.V.

uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands. It focuses on developing gene therapies for rare and serious diseases. The company's flagship product, HEMGENIX, helps people with hemophilia B manage bleeding risks. UniQure's lead candidate, AMT-130, is in clinical trials for Huntington's disease. The firm also explores gene therapies for conditions like epilepsy and amyotrophic lateral sclerosis (ALS). Founded in 1998, uniQure employs around 221 people and is led by CEO Matthew Kapusta.

Bottom Line

Matthew Kapusta's recent stock sale at uniQure N.V. is a notable insider transaction, though not part of a planned trading program. Investors keep a close watch on such moves for potential insights into company prospects. Shares of uniQure, which have seen significant institutional activity, traded near $46.37 recently. Analyst upgrades and strong buy ratings suggest a positive outlook for the company.